Finance

Lists
Why is KPTI down 7,45%?
Dive Deeper
KPTI:NASDAQ
Karyopharm Therapeutics Inc
0,80 USD
-7,45%
(-0,065) 1D
0,77 USD
-3,95% (-0,032)
After hours
Closed: 2-окт., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KPTI...
Open
0,86 USD
High
0,89 USD
Low
0,75 USD
Mkt. cap
18,13 млн
Avg. vol.
1,37 млн
Volume
2,34 млн
52-wk high
10,99 USD
52-wk low
0,75 USD
EPS
-12,84 USD
Beta
1,04
Shares outstanding
22,68 млн
No. of employees
228
Open
0,86 USD
High
0,89 USD
Low
0,75 USD
Mkt. cap
18,13 млн
Avg. vol.
1,37 млн
Volume
2,34 млн
52-wk high
10,99 USD
52-wk low
0,75 USD
EPS
-12,84 USD
Beta
1,04
Shares outstanding
22,68 млн
No. of employees
228
News stories
From web sources and news partners
About Karyopharm Therapeutics Inc
CEO-
Employees228
Founded2008
HeadquartersНьютон, Массачусетс, Америка Кошмо Штаттары
Sector-
Websitekaryopharm.com
Analyst ratings
Based on 6 analysts giving stock ratings to KPTI in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for KPTI in the last 3 months.
Highest
Current 0,80 USD
11,00 USD (+1 271,23%)
Average
6,54 USD (+715,26%)
Lowest
3,00 USD (+273,97%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Maintained
3,68 USD
+358,7%
09/01/2026
Brian Abrahams
RBC Capital
Buy
Maintained
8,00 USD
+897,3%
08/13/2026
Maury Raycroft
Jefferies
Buy
Maintained
11,00 USD
+1 271,2%
07/31/2026
Colleen M. Kusy
Robert W. Baird
Hold
Downgraded
-
-
07/31/2026
Edward Tenthoff
Piper Sandler
Buy
Maintained
7,00 USD
+772,6%
07/31/2026
Robert Burns
H.C. Wainwright
Hold
Downgraded
3,00 USD
+274%
07/31/2026
Unknown Analyst
Leerink Partners
Hold
Reiterated
7,00 USD
+772,6%
05/15/2026
Michael King
Rodman & Renshaw
Buy
Initiated
28,00 USD
+3 390,4%
03/09/2026
Last report
2026-ж., 13-авг.
Fiscal period
Q2 2026
EPS / Est. (USD)
-2,32 USD / -1,39 USD
-66,91%miss
Revenue / Est. (USD)
33,43 млн / 32,19 млн
+3,85%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
44,04 млн
34,08 млн
35,07 млн
33,43 млн
Cost of goods sold
32,66 млн
-96,47 млн
35,14 млн
30,04 млн
Cost of revenue
32,66 млн
-96,47 млн
35,14 млн
30,04 млн
Research and development expenses
-
125,62 млн
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26,61 млн
22,77 млн
26,68 млн
25,92 млн
Operating expense
26,61 млн
148,39 млн
26,68 млн
25,92 млн
Total operating expenses
59,26 млн
51,92 млн
61,83 млн
55,96 млн
Operating income
-15,22 млн
-17,84 млн
-26,76 млн
-22,53 млн
Other non operating income
-7,42 млн
-10,04 млн
16,41 млн
-32,08 млн
EBT including unusual items
-33,09 млн
-102,26 млн
-22,39 млн
-67,02 млн
EBT excluding unusual items
-33,09 млн
-39,90 млн
-22,39 млн
-67,02 млн
Income tax expense
34,00 миң
-67,00 миң
1,00 миң
-
Effective tax rate
-0,10%
0,07%
-
-
Other operating expenses
-
-
-
-
Net income
-33,13 млн
-102,20 млн
-22,39 млн
-67,02 млн
Net profit margin
-75,21%
-299,89%
-63,86%
-200,48%
Earnings per share
-3,82
-2,23
-1,24
-2,32
Interest and investment income
553,00 миң
607,00 миң
511,00 миң
722,00 миң
Interest expense
-11,01 млн
-12,62 млн
-12,55 млн
-13,14 млн
Net interest expenses
-10,46 млн
-12,01 млн
-12,04 млн
-12,42 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-15,10 млн
-17,82 млн
-26,75 млн
-22,52 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору